What is the level of liabilities of Epizyme this year?
Epizyme has a debt balance of 309.69 M USD this year.
Epizyme Liabilities 2024
Epizyme Liabilities
309.69 M USD
Ticker
EPZM
ISIN
US29428V1044
WKN
A1T9L2
In 2024, Epizyme's total liabilities amounted to 309.69 M USD, a 0% difference from the 0 USD total liabilities in the previous year.
Epizyme Aktienanalyse
What does Epizyme do?
Epizyme Inc is an American biotechnology company specializing in the development of therapeutic products for the treatment of cancer and genetic metabolic disorders. The company was founded in 2007 in Cambridge, Massachusetts. Epizyme focuses on developing drugs that target epigenetic changes in cells, which are changes in gene expression caused by changes in DNA structure. Epizyme specializes in the development of inhibitors of histone deacetylase enzymes (HDAC), which suppress the activity of enzymes involved in cell cycle regulation, apoptosis, and DNA repair. The company is divided into different business units focusing on different therapy areas, including oncology, hematologic oncology, and genetic metabolic disorders. In the field of oncology, Epizyme develops drugs for the treatment of blood and lymphatic system cancers such as diffuse large B-cell lymphoma and T-cell lymphoma. In the field of hematologic oncology, the company develops drugs for the treatment of blood disorders like myelodysplastic syndrome and acute myeloid leukemia. In the field of genetic metabolic disorders, Epizyme develops drugs for the treatment of lysosomal storage diseases. The company's business model primarily involves developing its own therapy products and collaborating with other biopharmaceutical companies and the pharmaceutical industry. Epizyme is listed on NASDAQ under the ticker symbol EPZM and has raised over $230 million in funding. Overall, Epizyme is an innovative company with a promising pipeline of drug candidates that works closely with other industry players to achieve its goals. It has established itself as a key player in the biotechnology industry. Epizyme ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Epizyme's Liabilities
Epizyme's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Epizyme's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Epizyme's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Epizyme's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Epizyme’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Epizyme stock
What were the liabilities of Epizyme compared to the previous year?
The liabilities of Epizyme have increased by 0% dropped compared to the previous year.
What are the consequences of high debt for investors of Epizyme?
High liabilities can pose a risk for investors of Epizyme, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Epizyme?
Low liabilities mean that Epizyme has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Epizyme affect the company?
An increase in liabilities of Epizyme can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Epizyme affect the company?
A decrease in the liabilities of Epizyme can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Epizyme?
Some factors that can influence the liabilities of Epizyme include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Epizyme so important for investors?
The liabilities of Epizyme are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Epizyme take to modify the liabilities?
To change its liabilities, Epizyme can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Epizyme pay?
Over the past 12 months, Epizyme paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Epizyme is expected to pay a dividend of 0 USD.
What is the dividend yield of Epizyme?
The current dividend yield of Epizyme is .
When does Epizyme pay dividends?
Epizyme pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Epizyme?
Epizyme paid dividends every year for the past 0 years.
What is the dividend of Epizyme?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Epizyme located?
Epizyme is assigned to the 'Health' sector.
Wann musste ich die Aktien von Epizyme kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Epizyme from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.
When did Epizyme pay the last dividend?
The last dividend was paid out on 9/29/2024.
What was the dividend of Epizyme in the year 2023?
In the year 2023, Epizyme distributed 0 USD as dividends.
In which currency does Epizyme pay out the dividend?
The dividends of Epizyme are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Epizyme stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Epizyme
Our stock analysis for Epizyme Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Epizyme Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
